#USA #New York #Class Action #Pomerantz Law Firm #Hims & Hers

Investor Alert: Class Action Lawsuit Filed Against Hims & Hers Health, Inc.

Overview

On August 22, 2025, Pomerantz LLP, a leading law firm, announced the initiation of a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS). This legal challenge has come at a crucial time as investors are encouraged to take action concerning their investments in the company before upcoming deadlines.

Details of the Lawsuit

This class action lawsuit is centered on the allegations that Hims & Hers, along with key executives and directors, may have engaged in securities fraud and other unlawful business practices. Investors who have suffered losses stemming from their investments in Hims & Hers are urged to make contact with Pomerantz LLP to explore their options.

To be eligible to become the Lead Plaintiff in this matter, investors must have purchased or acquired securities from Hims & Hers during the class period, which needs urgent attention as the deadline to file is set for August 25, 2025. Interested parties can reach out to Danielle Peyton at [email protected] or via phone at 646-581-9980.

Background of the Case

The lawsuit comes in the wake of significant developments involving Hims & Hers. On April 29, 2025, the company proudly announced a long-term collaboration with Novo Nordisk, which allowed for the sale of the FDA-approved Wegovy® on its platform. However, the situation took a dramatic turn when, on June 23, 2025, Novo Nordisk publicly terminated its partnership with Hims & Hers, attributing the decision to alleged deceptive practices by the company.

According to Novo Nordisk's press release, Hims & Hers purportedly promoted and sold illegitimate versions of their weight loss drug, Wegovy®, which compromised patient safety. The release stated that Hims & Hers had not only breached legal protocols but had also engaged in the mass sale of compounded drugs under misleading implications of personalization. Furthermore, it emphasized that the ingredients in these counterfeit versions of Wegovy® originated from unauthorized foreign manufacturers, raising severe concerns about safety and efficacy.

This scandal led to a significant decline in Hims & Hers' stock price, plummeting by $22.24 per share, which is a staggering 34.63% decrease, ending at $41.98 on the same day that news broke about the termination of the partnership.

About Pomerantz LLP

Pomerantz LLP is well-regarded in the legal industry, known for its commitment to upholding the rights of victims of violations in securities laws, antitrust issues, and corporate malfeasance. The firm was founded by Abraham L. Pomerantz, who is often referred to as the dean of the class action bar, and has successfully secured numerous multimillion-dollar damage awards in the past.

As a firm with a legacy stretching over 85 years, Pomerantz remains at the forefront of securities class actions, advocating vigorously for investor rights. For additional details regarding this lawsuit and how to participate, please visit www.pomerantzlaw.com.

Conclusion

In this turbulent time for Hims & Hers Health, Inc. investors have a crucial opportunity to make their voices heard in the upcoming class action lawsuit. Interested investors should act swiftly and consult with Pomerantz LLP to consider their eligibility and next steps. As the lawsuit is characterized by serious allegations regarding securities fraud and potential violations of regulations, it underscores the importance of vigilance and legal recourse for investors.